Hims & Hers Health, Inc. (NYSE:HIMS) Shares Sold by Oberweis Asset Management Inc.

Oberweis Asset Management Inc. decreased its position in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 10.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 843,600 shares of the company's stock after selling 100,000 shares during the period. Hims & Hers Health makes up about 1.0% of Oberweis Asset Management Inc.'s investment portfolio, making the stock its 26th largest position. Oberweis Asset Management Inc. owned 0.39% of Hims & Hers Health worth $20,398,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Crewe Advisors LLC bought a new position in Hims & Hers Health during the 4th quarter valued at about $28,000. Raleigh Capital Management Inc. boosted its position in shares of Hims & Hers Health by 1,100.0% during the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company's stock valued at $29,000 after buying an additional 1,100 shares during the period. Blume Capital Management Inc. grew its stake in shares of Hims & Hers Health by 100.0% during the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock valued at $29,000 after buying an additional 600 shares during the last quarter. Smartleaf Asset Management LLC raised its holdings in shares of Hims & Hers Health by 4,415.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company's stock worth $36,000 after buying an additional 1,413 shares during the period. Finally, Summit Securities Group LLC purchased a new stake in shares of Hims & Hers Health in the fourth quarter worth approximately $38,000. Hedge funds and other institutional investors own 63.52% of the company's stock.

Insider Activity

In other Hims & Hers Health news, CEO Andrew Dudum sold 100,000 shares of Hims & Hers Health stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $35.22, for a total transaction of $3,522,000.00. Following the completion of the sale, the chief executive officer now owns 27,918 shares of the company's stock, valued at approximately $983,271.96. The trade was a 78.18 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Irene Becklund sold 2,203 shares of the firm's stock in a transaction dated Thursday, April 3rd. The stock was sold at an average price of $28.78, for a total value of $63,402.34. Following the completion of the transaction, the insider now owns 8,007 shares of the company's stock, valued at approximately $230,441.46. The trade was a 21.58 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 712,998 shares of company stock worth $27,992,450. Insiders own 17.71% of the company's stock.

Hims & Hers Health Price Performance

NYSE HIMS traded up $0.42 during midday trading on Monday, hitting $28.51. 32,697,808 shares of the company traded hands, compared to its average volume of 15,717,696. Hims & Hers Health, Inc. has a 52 week low of $11.20 and a 52 week high of $72.98. The company's 50-day simple moving average is $34.24 and its 200-day simple moving average is $31.08. The company has a market cap of $6.33 billion, a PE ratio of 64.80 and a beta of 1.65.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its quarterly earnings data on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, beating analysts' consensus estimates of $0.09 by $0.02. The company had revenue of $481.14 million for the quarter, compared to the consensus estimate of $494.56 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. On average, research analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Wall Street Analysts Forecast Growth

HIMS has been the topic of several research analyst reports. Truist Financial cut their price objective on Hims & Hers Health from $39.00 to $33.00 and set a "hold" rating on the stock in a research report on Thursday, April 10th. Morgan Stanley cut shares of Hims & Hers Health from an "overweight" rating to an "equal weight" rating and upped their price target for the stock from $42.00 to $60.00 in a report on Tuesday, February 18th. Leerink Partners raised their price target on shares of Hims & Hers Health from $24.00 to $40.00 and gave the stock a "market perform" rating in a research note on Tuesday, February 25th. Citigroup lowered their price objective on shares of Hims & Hers Health from $27.00 to $25.00 and set a "sell" rating for the company in a research report on Friday. Finally, Needham & Company LLC raised their target price on shares of Hims & Hers Health from $31.00 to $61.00 and gave the stock a "buy" rating in a research report on Tuesday, February 25th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $38.08.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.